Direct Answer
Merck's investment thesis centers on the Keytruda (pembrolizumab) oncology franchise, the world's top-selling drug at approximately $29.5 billion in FY2024 revenues. Five layers of competitive advantage support the thesis: Keytruda's unmatched label breadth across more than 40 cancer indications, a near-monopoly HPV vaccine franchise in Gardasil 9, Animal Health segment diversification, exceptional R&D scale at approximately $18 billion annually, and a global commercial infrastructure built over decades as MSD internationally. The central risk is a US composition-of-matter patent expiry for Keytruda in 2028, which at approximately 46% of FY2024 revenues creates a concentration risk of unusual magnitude for a large-cap pharmaceutical company.
What is Merck's competitive moat?
Merck's durable advantage is not a single product feature but the accumulated depth of an oncology franchise supported by a vaccines monopoly, diversified earnings from Animal Health, R&D scale that few pharmaceutical companies can match, and commercial infrastructure built over six decades. Five distinct layers work together.
1. Keytruda franchise and oncology leadership
Keytruda (pembrolizumab) is the world's top-selling drug at approximately $29.5 billion in FY2024 revenues. It is a PD-1 immune checkpoint inhibitor approved in more than 40 cancer indications, making it the most broadly used cancer immunotherapy available. The breadth of approvals is supported by hundreds of active clinical trials running simultaneously, a scale of evidence generation that Merck's competitors cannot easily replicate. Oncologists default to Keytruda as the backbone of combination regimens not because of inertia but because the data supporting its use is more extensive than for any competitor.
Competitor PD-1 and PD-L1 inhibitors exist: Bristol-Myers Squibb's Opdivo, Genentech's Tecentriq, and AstraZeneca's Imfinzi all hold approved indications. None matches Keytruda's label breadth or the volume of supporting trial data accumulated since the drug's first approval in 2014. Oncologist familiarity compounds over time as clinicians gain experience reading Keytruda outcomes in practice, not just in trials.
2. Gardasil HPV vaccine franchise
Merck's Gardasil franchise for human papillomavirus prevention represents a near-monopoly in a public health essential. Gardasil 9 covers nine HPV strains linked to cervical cancer, oropharyngeal cancer, anal cancer, and genital warts. No comparable competitor has achieved the same breadth of coverage with equivalent global approval status. The vaccine's status as a cervical cancer prevention tool has driven government-mandated vaccination programs across more than 130 countries.
Long-term global expansion in lower-income countries, where HPV vaccine penetration remains low relative to the disease burden, and the expanding male vaccination market provide a multi-decade demand runway. Short-term volatility from the 2023 to 2024 China destocking event (where distributor inventory accumulated ahead of demand normalization) represents a timing disruption rather than a structural loss of the franchise. China had represented approximately 30 to 40 percent of Gardasil revenues before the disruption, and normalization is uncertain in timing.
3. Animal Health segment diversification
Merck's Animal Health segment generated approximately $5.8 billion in FY2024, providing meaningful earnings diversification outside the human pharmaceutical patent cycle. Products including Bravecto (flea and tick prevention for companion animals) generate recurring consumer spending that is relatively immune to drug patent cliffs, regulatory price controls, and the oncology competitive dynamics that dominate the human pharma business. Animal Health grows with pet ownership trends and the humanization of pet care in developed markets, providing a stable earnings base alongside the more volatile human pharmaceutical segment.
4. R&D scale and pipeline depth
Merck invests approximately $18 billion annually in R&D, placing it among the top three pharmaceutical companies globally by absolute research spending. This scale allows the company to run hundreds of Keytruda combination trials simultaneously while also funding exploration of entirely new mechanisms. The late-stage pipeline includes MK-1084 (an oral GLP-1 receptor agonist for obesity and diabetes), V116 (a pneumococcal vaccine for adults aged 50 and older), clesrovimab (RSV prophylaxis for infants), and multiple MK-7240 (an IL-23 inhibitor) candidates for inflammatory bowel disease.
Scale is the key moat attribute here. A smaller pharmaceutical company cannot run 100 Keytruda combination trials while simultaneously developing a GLP-1 obesity drug and a next-generation pneumococcal vaccine. The R&D machine that produced Keytruda can, in principle, produce additional blockbusters, though the probability of any individual program succeeding remains uncertain.
5. Global commercial infrastructure
Merck operates internationally as MSD (outside the United States and Canada), with dedicated sales forces, medical affairs teams, and regulatory departments across all major global markets. This infrastructure enables rapid launch of new products in markets where approval is obtained. Regulatory expertise across the US FDA, European Medicines Agency, Japan's PMDA, and China's NMPA provides a meaningful barrier to entry: a new pharmaceutical company cannot launch a global product without years of relationship-building with these agencies and the operational capacity to manage multi-country submissions simultaneously.
Revenue mix and financial profile
Merck's revenue base is concentrated in pharmaceuticals with Animal Health providing diversification. Within pharmaceuticals, the concentration in Keytruda is the defining financial characteristic.
| Segment / Product | Approximate FY2024 | Key Driver |
|---|---|---|
| Keytruda (pembrolizumab) | ~$29.5B | Oncology volume across 40+ approved indications globally |
| Gardasil / Gardasil 9 | ~$8.6B | HPV vaccine uptake; near-term headwind from China destocking |
| Animal Health | ~$5.8B | Companion animal and livestock products (Bravecto, Nobivac) |
| Other Pharmaceuticals | ~$20B+ | Hospital products, specialty, Januvia franchise (declining) |
| Total Revenues | ~$63B | Keytruda at approximately 46% of total revenues |
The concentration in Keytruda is both the source of Merck's strength and its central vulnerability. A single drug generating 46% of total revenues is unusual among large-cap pharmaceutical companies. Merck's operating margins are high by pharmaceutical standards (approximately 30% or higher at the operating level in recent years), driven by Keytruda's pricing power and the scale efficiencies of the global commercial infrastructure.
The Gardasil destocking in China illustrates how quickly a second revenue pillar can shrink: what was a stable high-growth business became a headwind within 12 months. Investors need to distinguish between transient timing disruptions (China distributor inventory normalization) and structural threats (a domestic Chinese HPV competitor reaching full scale).
Key risks to the investment thesis
1. Keytruda patent cliff in 2028
Keytruda's US composition-of-matter patent expires in 2028. At approximately 46% of FY2024 revenues, this creates concentration risk of unusual magnitude. Biosimilar entry into the PD-1 inhibitor market could erode US revenues by 30 to 50 percent within two years of patent expiration, based on historical biosimilar penetration rates for large-molecule biologics.
Merck is attempting to address this through two mechanisms. First, it is developing a subcutaneous (SC) formulation of Keytruda that would have its own patent life and offer a faster, more convenient administration route versus the current intravenous infusion. Second, MK-7684A is a next-generation PD-1/VEGF bispecific antibody designed as a follow-on in tumor types where Keytruda is already the standard of care. Neither mechanism guarantees revenue replacement at the scale required.
2. Gardasil China exposure
China represented approximately 30 to 40 percent of Gardasil global revenues before the 2023 to 2024 destocking event. The underlying causes include distributor over-ordering in prior years and Chinese government efforts to develop domestic HPV vaccine alternatives. Domestic Chinese competitors at lower price points could structurally reduce Merck's market share in China's publicly funded vaccination programs even after inventory normalization. Recovery to pre-disruption revenue levels in China is not guaranteed.
3. R&D execution risk across the pipeline
Merck's post-Keytruda growth depends on pipeline success. The GLP-1 market (MK-1084) is dominated by Eli Lilly's tirzepatide and Novo Nordisk's semaglutide, both of which have years of clinical data, commercial infrastructure, and manufacturing scale that Merck would have to overcome as a later entrant. Clinical failure of two or three key late-stage programs would leave a structural revenue gap after 2028 that acquisitions alone may not fill, given the regulatory and timeline risks of large pharmaceutical mergers.
4. IRA drug pricing reform
The Inflation Reduction Act authorizes Medicare to negotiate prices for select high-revenue drugs. Keytruda is a candidate for negotiation in current and future rounds. A first-round negotiated price takes effect from 2028, the same year the composition-of-matter patent expires. These two events compounding in the same year represent a significant near-simultaneous headwind: negotiated lower prices in the Medicare channel and biosimilar competition in the commercial channel. The magnitude of IRA impact depends on the negotiated price discount and the Medicare share of Keytruda revenues.
5. Litigation exposure
Merck faces ongoing litigation related to legacy Vioxx claims, Gardasil (plaintiffs alleging adverse events linked to HPV vaccination), and patent challenges on various products. The Vioxx liability, while largely resolved over prior decades, established a precedent for large pharmaceutical product-liability settlements. Gardasil litigation uncertainty represents a sentiment risk for investors and a potential ongoing legal cost, though the scientific consensus on Gardasil's safety and efficacy is strong and regulatory agencies have not changed their recommendations.
Frequently Asked Questions
What is Merck's primary competitive advantage?
Merck's most durable competitive advantage is the Keytruda (pembrolizumab) franchise. Keytruda is the world's top-selling drug at approximately $29.5 billion in FY2024 revenues and carries approval in more than 40 cancer indications. The breadth of approvals, supported by hundreds of ongoing clinical trials, creates network effects where oncologists default to Keytruda as the backbone of combination regimens. Competitor PD-1/PD-L1 inhibitors such as Opdivo, Tecentriq, and Imfinzi exist, but Keytruda's label breadth and deep oncologist familiarity represent a durable advantage that has compounded over more than a decade of clinical investment.
When does Keytruda's patent expire and what does that mean for investors?
Keytruda's US composition-of-matter patent expires in 2028. Because Keytruda represents approximately 46% of Merck's FY2024 revenues, patent expiry creates significant concentration risk. Biosimilar entry could erode revenues by 30 to 50 percent within two years of patent expiration. Merck is developing a subcutaneous formulation of Keytruda with a new patent life and a next-generation PD-1/VEGF bispecific antibody (MK-7684A) to extend the franchise, but the potential revenue gap between Keytruda peak sales and pipeline contributions is very large and represents the central investment risk for the next decade.
How does Gardasil contribute to Merck's long-term growth?
Gardasil 9, Merck's HPV vaccine covering nine cancer-linked HPV strains, functions as a near-monopoly public health essential in cervical cancer prevention. Long-term global expansion into lower-income countries and male vaccination programs provides a multi-decade demand runway. However, short-term revenue from China was disrupted in 2023 and 2024 due to a destocking event at Chinese distributors. China represented approximately 30 to 40 percent of Gardasil revenues before that disruption. Normalization of China Gardasil volumes is uncertain in timing and magnitude.
What is the impact of the Inflation Reduction Act on Merck?
The Inflation Reduction Act allows Medicare to negotiate prices for certain high-revenue drugs. Keytruda is a candidate for negotiation in current and future negotiation rounds. The first negotiated price applies from 2028, which compounds with the patent expiry that also takes effect that year. IRA-negotiated price reductions in US revenues for Keytruda could materially shrink Merck's revenue base in the latter part of the 2020s, layered on top of biosimilar competition from patent expiration.